Therapeutic strategies targeting these pathways are emerging, including SOCE inhibitors for autoimmune diseases, TRP channel modulators to skew polarization toward M2 phenotypes in fibrosis, and STIM1/Orai1 antagonists in clinical trials (Wulff et al., 2019). This evidence concerns the gene STIM1 and autoimmune disease.